ROME, Italy—In elderly patients treated with prasugrel after undergoing stenting for ACS, use of platelet function testing to either adjust their dose or switch them to clopidogrel had no effect on ...

For patients undergoing percutaneous coronary intervention (PCI), tailoring antiplatelet therapy based on the results of platelet function testing makes no difference in the risk of recurrent ischemic ...

LOS ANGELES — Patients with intracranial aneurysm who respond poorly to the antiplatelet drug clopidogrel when treated with flow diversion using the Pipeline embolization device (Medtronic) have ...

BARCELONA, SPAIN — A new "deescalation" regimen of dual antiplatelet therapy post-ACS—which involves switching from prasugrel (Effient, Lilly/Daiichi-Sankyo) to clopidogrel in certain patients guided ...

This release is available in Chinese. An analysis of six tests that are used to measure platelet function and help gauge the effectiveness of antiplatelet drugs for patients undergoing a cardiac ...

CHICAGO – Among patients with acute coronary syndromes undergoing a procedure such as angioplasty, those who received platelet function tests before receiving antithrombotic therapy to determine ...

ROME -- Platelet function monitoring in elderly patients did not improve clinical outcomes after percutaneous coronary intervention (PCI) for an acute coronary syndrome, ANTARCTIC investigators found.

Approximately 40% of adolescent women experience heavy menstrual bleeding (HMB), and 10–62% of them have an underlying bleeding disorder (BD). Diagnosing a BD remains challenging because of ...

While thrombocytopenia and bleeding are events that often occur together in neonates, this may not signify cause and effect. In fact, one study reported that 91% of neonates with low platelet counts ...

Thrombocytopenia absent radius (TAR) affects the radius — the long, thin bone in the forearm — and platelet function. This defect commonly appears at birth or within the first few years of life.

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...